Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $81.33

Keros Therapeutics, Inc. (NASDAQ:KROS) has been given a consensus rating of “Moderate Buy” by the fourteen ratings firms that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $81.33.

A number of brokerages have weighed in on KROS. Guggenheim downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Jefferies Financial Group initiated coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company. Scotiabank decreased their price objective on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a report on Friday, December 13th. Finally, Oppenheimer dropped their price objective on shares of Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating on the stock in a research report on Monday, December 16th.

Keros Therapeutics Trading Up 0.7 %

NASDAQ:KROS opened at $17.03 on Wednesday. The firm has a fifty day simple moving average of $54.97 and a 200 day simple moving average of $51.59. Keros Therapeutics has a 1-year low of $15.67 and a 1-year high of $73.00. The stock has a market capitalization of $689.83 million, a PE ratio of -3.27 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period in the previous year, the business posted ($1.33) earnings per share. On average, equities analysts predict that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares in the last quarter. KBC Group NV increased its stake in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the period. Point72 Asia Singapore Pte. Ltd. increased its stake in Keros Therapeutics by 36.7% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock worth $223,000 after acquiring an additional 1,033 shares during the period. Arizona State Retirement System raised its holdings in Keros Therapeutics by 16.3% in the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after acquiring an additional 1,130 shares in the last quarter. Finally, Algert Global LLC lifted its position in shares of Keros Therapeutics by 10.6% during the 2nd quarter. Algert Global LLC now owns 15,700 shares of the company’s stock valued at $717,000 after acquiring an additional 1,505 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.